<DOC>
	<DOCNO>NCT01735396</DOCNO>
	<brief_summary>This pilot study abiraterone acetate African American/Black patient castration-resistant prostate cancer . The primary objective determine correlation germline polymorphisms antitumor activity ( defined decline PSA ≥ 30 % ) African American patient castration-resistant prostate cancer treat abiraterone acetate . Patients receive abiraterone acetate time disease progression , absence prohibitive toxicity . Patients follow disease progression survival .</brief_summary>
	<brief_title>Abiraterone Acetate Trial African American Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>1 . Have sign inform consent document indicate subject understand purpose procedure require study willing participate study Be willing/able adhere prohibition restriction specify protocol Written Authorization Use Release Health Research Study Information African American Black ( self identification ) Male age 18 year Histologically cytologically confirm adenocarcinoma prostate Metastatic disease document standard image Progressive prostate cancer base either rise PSA , new bone metastasis , progression measurable disease accord PCWG2 12 guideline . Patients either follow clinical state eligible enrollment : . No prior chemotherapy ; ii . Patients previously treat 12 prior chemotherapy regimen permit , one must include docetaxel Surgically medically castrate , testosterone level &lt; 50 ng/dl . Patients previously treat antiandrogen must demonstrate progression antiandrogen . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 Have baseline serum potassium ≥ 3.5 mEq/L Have aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , bilirubin level &lt; 1.5 x ULN Have serum albumin ≥ 3.0 g/dL Total bilirubin ≤ 1.5 x ULN Have platelet count ≥ 100,000/μL Have absolute neutrophil count &gt; 1500 cell/mm3 Have calculate creatinine clearance ≥ 60 mL/min Have hemoglobin ≥ 9.0 g/dL Able swallow study drug whole tablet Willing take abiraterone acetate empty stomach ; food consume least two hour least one hour dose abiraterone acetate take Patients partner childbearing potential must willing use method birth control adequate barrier protection determine acceptable principal investigator study 1 week last dose abiraterone acetate Active infection medical condition would make prednisone/prednisolone ( corticosteroid ) use contraindicate Known brain metastasis Uncontrolled hypertension ( systolic BP ≥ 160 mmHg diastolic BP ≥ 95 mmHg ) Patients history hypertension allow provide blood pressure control antihypertensive treatment Active symptomatic viral hepatitis chronic liver disease History pituitary adrenal dysfunction Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , New York Heart Association ( NYHA ) Class IIIIV heart disease cardiac ejection fraction measurement &lt; 50 % baseline Administration investigational therapeutic within 30 day screen Have condition , opinion investigator , would compromise wellbeing subject study prevent subject meeting performing study requirement Have poorly control diabetes Have history gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study agent Have preexist condition warrant longterm corticosteroid use excess study dose Have know allergy , hypersensitivity , intolerance abiraterone acetate prednisone excipients</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>African American men</keyword>
	<keyword>metastatic prostate cancer</keyword>
	<keyword>castration resistant</keyword>
</DOC>